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Abstract
The Expected Value of Sample Information (EVSI) is used to calculate
the economic value of a new research strategy. While this value would be
important to both researchers and funders, there are very few practical
applications of the EVSI. In the main, this is due to computational diffi-
culties associated with calculating the EVSI in practical health economic
models using nested simulations. We present an approximation method
for the EVSI that is based on estimating the distribution of the posterior
mean of the incremental net benefit across all the possible future samples,
known as the distribution of the preposterior mean. Specifically, we sug-
gest that this distribution is estimated using moment matching coupled
with simulations that are available for probabilistic sensitivity analysis,
which is typically mandatory in health economic evaluation. We demon-
strate that this method is successful using an example that has previously
been applied to other EVSI approximation methods. We then conclude
by discussing how our method fits in with other recent additions to the
literature that detail approximation methods for the EVSI.
Value of Information (VoI) analysis [23] has frequently been touted as an
extension to probabilistic sensitivity analysis (PSA) [17, 18, 13, 14, 1, 6, 10, 20].
Generally speaking, VoI analyses quantify the potential economic benefit of
performing new research targeting uncertainty in an underlying economic model.
In the past, these measures have focused on estimating the economic benefit of
resolving all the uncertainty in the model. While this is simple to calculate
computationally, it has limited practical value, especially in models where the
benefit is high, as model uncertainty can almost never be fully resolved.
Arguably, therefore, the VoI measure that is most useful in practice is known
as the Expected Value of Sample Information (EVSI) [33, 32], which measures
the potential economic benefit of some specific future research. This value de-
rives directly from the possibility that the new information gleaned from the
research could help a payer avoid wasting resources on an inefficient treatment
which would, however, have been deemed cost-effective given the current knowl-
edge about the underlying model inputs.
1
ar
X
iv
:1
61
1.
01
37
3v
3 
 [m
ath
.ST
]  
7 S
ep
 20
17
Despite the obvious benefits of calculating the EVSI, especially in terms
of efficiently using research and development budgets, practical applications
of EVSI calculations are scarce [34]. Initially, this was because the published
approaches to calculating the EVSI were based on computationally intensive
nested Monte Carlo (MC) procedures [9]. Some older methods avoid the need for
nested simulation by assuming certain model conditions such as independence
in the model parameters and linearity [1], which reduced the computation time
but limited the applicability of these methods.
More recently, EVSI research has been active and this has led to the proposal
of several alternative calculation methods. Some of these more recent methods
calculate the EVSI for specific designs, such as cluster randomised clinical trials
[41, 8, 1], while others use approximations to avoid using nested simulations [7,
25, 24]. The most recent approaches have been developed to avoid rerunning the
economic model, which means that the EVSI can be calculated using the samples
that have already been obtained to perform the, often mandatory, probabilistic
sensitivity analysis (PSA) [27, 37]. These methods may be suitable in certain
situations, especially in settings where each model run requires a large amount of
computational time. However, they either require the specification of sufficient
statistics or a large number of matrix calculations.
In this paper, we present a new computation method for the EVSI that can
be used irrespective of the underlying structure in the health economic model.
The method is based on determining the properties of a specific function of
the net benefit. We suggest an approximation based on these properties and
then demonstrate how this can be used to calculate the EVSI. Specifically, the
approximation reuses PSA samples from the underlying model alongside a small
number of estimates of the variance of the incremental net benefit obtained
by rerunning the model. Therefore, this method relies on around 30 nested
simulations compared to at least 600 [28] for a standard EVSI analysis.
In models with a relatively short run time, our method has a similar com-
putational cost to more recent alternatives. It is also simple to implement for
virtually all model structures and realistic trial designs, possibly accounting for
missingness or problems with follow-up, as it relies simply on Bayesian updating
and variance calculations. Most importantly, the required Bayesian updating
is in the same form as the analysis that would be required once the data are
collected, which aligns the model used to plan the study with the one used for
the actual data analysis. This is not always the case with traditional meth-
ods, when sample size calculations are based on simplistic approximations and
analytic formulæ.
The presentation of our method begins in §1 with the introduction of no-
tation and other key concepts. The estimation method is then presented in §2
and it is implemented for an example from Ades et al. [1] in §3. Finally, we
conclude with a discussion of the computational burden of this method and how
this compares to other methods. This allows for the recommendation of when
this new tool may be more suitable than the alternatives.
2
1 Notation and Concepts
The EVSI is calculated as the difference between the value of the decision made
under the current level of uncertainty and the expected value of the decision
made with the additional information contained in the future trial. To present
both the EVSI and our method more formally, we begin by introducing some
notation and key concepts. First, we assume that the health economic model
is defined using a set of parameters, denoted θ. To perform Probabilistic Sen-
sitivity Analysis (PSA), the current level of uncertainty in these parameters,
based on literature reviews, clinical trials or meta analyses, is defined using a
probability distribution p(θ) [5].
To calculate the EVSI, it is assumed that T treatments are under consid-
eration. To compare these treatments, we define the net benefit of each treat-
ment t = 1, . . . , T based on these model parameters, which we indicate as NBθt .
Strictly speaking, we assume that NBθt does not reflect individual level uncer-
tainty so if all the θ values were known with certainty then NBθt would be a
fixed number. The value of the best decision under current information is the
treatment with the maximum net benefit value
max
t
Eθ
[
NBθt
]
.
The EVSI is concerned with a trial in which we gain “more information” by
gathering a new dataset X. This new dataset is what we would collect in the
future trial, for example the number of patients responding to a treatment or
the number of false positive test results. These data are useful as they provide
us with more information about the underlying model parameters which, in
turn, influence the decision. Specifically, if the future trial had already been
undertaken and the data observed as x, the optimal decision conditional on
that observed sample would be
max
t
Eθ|X=x
[
NBθt
]
,
where the expectation of the net benefit is taken over the distribution of the
parameters conditional on the information in the sample x.
However, as new research has not been carried out yet and the data X have
not been observed, the EVSI is calculated by averaging over all possible future
datasets to give the average value of the decision made with the additional
information contained in the sample;
EVSI = EX
[
max
t
Eθ|X
[
NBθt
]]
−max
t
Eθ
[
NBθt
]
. (1)
In general, the distribution of all the possible future samples is defined using the
same distribution that would be used to model the data if it had been observed
[37, 27]. Formally, this means that the distribution of X is defined through
its relationship with θ, this allows us to sample values from the distribution of
p(X) as we will see in §2.3.
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The analysis required for the EVSI is exactly the analysis that would be
required if the statistical modelling underpinning the health economic model
was inferred using Bayesian methods. In this setting, the PSA distributions
for the parameters would be called the prior for θ and this prior is combined
with the data X to update the information about the model parameters and
determine a posterior distribution for the parameters θ conditional on the data
X. In fact, in Bayesian analysis, the inner expectation in the first term of
equation (1) is known as the preposterior mean, i.e. the posterior mean before
the data have been collected. The preposterior mean, which we will denote µXt ,
is the key element in the EVSI calculation and it is also the term that makes
the EVSI computationally expensive, as it has traditionally been estimated
by simulation. In the most general setting, this requires posterior updating,
usually with Markov Chain Monte Carlo (MCMC) methods, which are very
computationally intensive.
Therefore, all the approximation methods [1, 7, 24, 37, 27] focus on estimat-
ing this preposterior mean without using full MCMC sampling. Our approx-
imation reuses the information contained in NBθt to estimate the preposterior
mean or more specifically the distribution of the preposterior mean. The concept
of “distribution of a mean” is rather counterintuitive in a standard statistical
analysis. However, it makes sense in this context, because we are interested
in the posterior before the data have been collected. This implies that there is
uncertainty as to which of all the possible future samples will occur, were we to
conduct the study. Each possible sample would yield a different posterior mean
and so the sampling distribution for the data induces a distribution over the
posterior means. To make this more clear, we use a simple example, which is
also used to highlight how NBθt can be used to approximate this distribution.
1.1 The distribution of the preposterior mean – an exam-
ple
Suppose that a new drug is available and is associated with a probability θ
of curing a particular disease. As this drug is new, we assume that there is
very limited evidence on its effectiveness. This could be expressed, in a very
simplistic way, by assuming that all values for θ, between 0 and 1, are equally
likely. Mathematically, this is equivalent to modelling θ ∼ Uniform(0, 1). Of
course, in practical settings, it is likely that information about the effectiveness
of the treatment is available and this could be easily included by using an
alternative distribution for p(θ).
In this simple model, the treatment is effective if the disease has been cured
and the drug costs are known to be equal to c. As we are only interested in
population level effectiveness, the effectiveness of the treatment is the probability
of a cure θ. We finally assume that the decision maker is prepared to pay k
monetary units for each person that is cured of the disease.
To simplify this example further, the new treatment is being compared with
the current standard of care, which is to leave the disease untreated. This option
has no cost but also has no effectiveness as this (non-life-threatening) disease
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does not improve without drug intervention. Thus, the two net benefit values
are
NBθ1 = 0 and NB
θ
2 = kθ − c.
The trial involves giving N people the drug and observing how many are
cured. This means that the sampling variability can be characterised using a
Binomial distribution X | θ ∼ Binomial(N, θ), with θ the probability of being
cured. The distribution p(X | θ) and the prior for θ can then be combined to
give the predictive distribution of the future samples X as
p(X) =
∫ 1
0
p(X | θ)p(θ) dθ
=
∫ 1
0
(
N
X
)
θX(1− θ)N−X × 1 dθ
=
X!(N −X)!N !
(N + 1)!X!(N −X)! =
1
N + 1
.
This calculation implies that, if we begin by assuming that all values for θ are
equally likely, then all values of the future sample are equally likely. This is
because the possible values for X, the number of people cured, are 0, 1, . . . , N
and each of them has probability 1N+1 .
Once the distribution for the possible data values is known, the distribution
of the preposterior mean is found by calculating the posterior mean for both
the net benefit functions. As NBθ1 does not depend on θ, the posterior mean
for NBθ1 is µ
X
1 = 0. Therefore, the preposterior mean for NB
θ
1 does not have a
distribution in this example and is just equal to 0. However, the posterior mean
for NBθ2 does depend on the future sample X:
µX2 = Eθ|X
[
NBθ2
]
=
∫ 1
0
(kθ − c) p(θ | X) dθ
= k
(∫ 1
0
θ p(θ | X) dθ
)
− c
= k
1 +X
2 +N
− c,
as the second integral is exactly the mean of θ | X and it can be shown that
θ | X ∼ Beta(1+X, 1+N). Therefore, the distribution of µX2 is directly related
to the distribution of X, which assumes that all values for X are equally likely
and thus all values of µX2 are equally likely. However, this belief for X is a
direct result of our initial beliefs that all values of θ are equally likely. In this
sense, the distribution of the preposterior mean is strongly linked to our initial
beliefs about θ which are encoded in our prior distribution. The supplementary
material presents two alternative models in order to demonstrate that the prior
distribution for θ is similar to the distribution of the preposterior mean, in many
settings.
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2 Estimating the distribution of the preposte-
rior mean
Historically, EVSI calculations have been carried out by estimating the distri-
bution of the preposterior mean by Monte Carlo simulation [31, 9, 1] or by
approximating the relationship between the samples X and the posterior mean
[37, 1]. However, we have just demonstrated that the distribution of the pre-
posterior mean for the net benefit, which we will indicate with p(µXt ), is related
to the prior for the model parameters. More importantly, in health economic
evaluations, PSA samples from the prior are already available when the EVSI
is being calculated [5, 3, 2]. Therefore, these PSA samples can be used to save
computational time when estimating p(µXt )
1. Specifically, our method estimates
p(µXt ) using the PSA samples and additional knowledge about the mean and
variance of the preposterior mean, which are both estimated by simulation.
2.1 Expectation and Variance for the preposterior mean
To estimate the mean and variance of µXt , we use formulæ for conditional iter-
ated expectation [40]. Firstly, this implies that the mean of µXt is given by
EX
[
µXt
]
= EX
[
Eθ|X
[
NBθt
]]
= Eθ
[
NBθt
]
,
i.e. the average of the preposterior mean is equal to the mean of the NBθt , which
can be obtained using the PSA samples for the net benefit. This implies that
performing the EVSI analysis, i.e. considering the possible values of a future data
set before obtaining data, cannot give any additional information or change our
current decision, as on average the optimal decision would remain the same. To
actually change the optimal decision the research must be carried out.
Secondly, the variance of the preposterior mean is given by
VarX
[
µXt
]
= VarX
[
Eθ|X
[
NBθt
]]
= Varθ
[
NBθt
]
− EX
[
Varθ|X
[
NBθt
]]
.
In other words, the variance of the preposterior mean is equal to the variance
of the net benefit minus the average posterior variance, over all possible future
samples.
Therefore, to calculate the mean and variance of the preposterior mean by
simulation, we only need to estimate the average posterior variance over all
possible samples X, as long as the PSA samples have already been obtained.
Most importantly, §2.3 demonstrates that a suitable estimate of the expected
posterior variance can be obtained using only a small number of simulated future
samples. This significantly reduces the number of samples required to calculate
the EVSI compared to standard simulation based methods.
1Menzies [27] also uses the similarity between the PSA samples for the net benefit and the
distribution of the preposterior mean as a basis for his method but the proposed transforma-
tions differ significantly.
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2.2 Moment Matching
Assuming that the mean and variance of the preposterior mean have been esti-
mated, p
(
µXt
)
can be approximated using moment matching [12, 19]. In general,
this involves approximating p
(
µXt
)
by taking a known distribution and ensuring
that the mean and variance of this distribution equal the mean and variance of
p
(
µXt
)
. For example, this moment matching method could involve approximat-
ing the distribution of the preposterior mean by a Normal distribution with the
correct mean and variance.
However, this strategy is unlikely to give accurate estimates, as the EVSI
is strongly influenced by the tails of the distribution of the preposterior mean
because this is where the optimal decision is most likely to change. Therefore,
the EVSI estimate will be significantly improved if the distribution of the pre-
posterior mean is approximated by moment matching with the PSA samples for
NBθt . As these samples represent our initial beliefs about the net benefit of each
treatment and, as seen in §1.1, our initial beliefs have a strong impact on the
shape of p(µXt ).
2.2.1 Linear transformation to moment match
In practice, we suggest that a linear transformation of the NBθt should be used to
estimate the distribution of the preposterior mean by moment matching. This
involves estimating the constants a and b such that aNBθt + b has the same
mean and variance as p(µXt ):
Eθ
[
a NBθt + b
]
= EX
[
µXt
]⇒ aEθ [NBθt ]+ b = Eθ [NBθt ]
Varθ[a NB
θ
t + b] = VarX [µ
X
t ]⇒ a2Varθ[NBθt ] = σ2,
where σ2 is the variance of the preposterior mean that is calculated as the
difference between the variance of the net benefit and the expected posterior
variance. Solving for a and b yields
a =
√√√√ VarX [µXt ]
Varθ
[
NBθt
] = σ√
Varθ
[
NBθt
] and b = Eθ [NBθt ] (1− a), (2)
which depend on the expectation and variance of the net benefit and its expected
posterior variance.
Interestingly, these constants allow for a relatively simple interpretation of
the approximation of p
(
µXt
)
. The constant a is related to the reduction in the
net benefit variance that will be obtained by learning X. This means that the
more information X contains about the net benefit, the higher the value of a.
In some ways, we can think of this as the amount of variance that is “explained”
by the fact that we have not yet observed X.
The constant b is then the mean of the preposterior distribution weighted
by one minus this explained variance where the weight is related to how much
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information is contained in X. Thus, the density of the preposterior mean is
estimated as a convex combination of our initial beliefs about the net benefit
and the mean of the net benefit (which is also the mean of the preposterior
distribution).
In general, the higher the sample size of X, the more information it contains
and therefore the higher the value of a. This implies that as the sample size in
the data collection exercise increases, our approximation for p(µXt ) approaches
the PSA samples for the net benefit, i.e. an infinite future sample implies that
the distribution of the preposterior mean is exactly equal to our initial beliefs
about the net benefit. We explore this slightly counterintuitive result in detail
in the supplementary material along with further motivation for our moment
matching method. Note that, as a rule of thumb, the approximation is most
accurate when the sample size of the future dataset is greater than 20, especially
when the data are discrete, as in §1.1.
As PSA simulations for the net benefit are generally available as a component
of a full economic analysis [5, 3, 2], these samples can be used to estimate the
mean and variance of NBθt . These mean and variance values can then used
to calculate a and b. Additionally, the PSA simulations can be rescaled using
these constants so the only additional element required to approximate the
distribution of the preposterior mean is an estimate of the expected variance of
the posterior net benefit across different possible future samples X.
2.3 Estimating the expected variance of the posterior net
benefit
We suggest that the expected variance of the posterior net benefit should be
estimated by simulation. While this seems computationally intensive, the num-
ber of simulations can be kept fairly low as the posterior variance is relatively
stable across different future samples X, meaning that the variance does not
change substantially for different samples. This stability is most extreme when
the data distribution and our initial beliefs are both normal. In this case, the
posterior variance is the same irrespective of the posterior mean as it is only
related to the variance of the sample X and the sample size.
In non-normal settings (e.g. involving the collection of data for costs or util-
ity measures), the posterior variance is no longer unrelated to the mean of the
sample X. However, as demonstrated in the supplementary material, a small
number of “posterior” samples (around 20-50) can be used to estimate the ex-
pected posterior variance accurately, even in highly non-normal settings. Cru-
cially, this result is dependent on intelligently choosing which posterior samples
to use.
Specifically, we need to calculate the expected posterior variance:
EX
[
Varθ|X
[
NBθt
]]
= Eθ
[
EX|θ
[
Varθ|X
[
NBθt
]]]
,
where the two outer expectations on the right hand side estimate the expectation
over all possible values of X. In general, we need to choose a small number of θ
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values whilst ensuring that the full range of θ values is explored before sampling
one future sample conditional on each value of θ. This estimates the expected
posterior variance accurately using quadrature [15].
In most health economic models θ contains a large number of parameters,
sometimes upwards of 1000 [39]. However, most trials are only designed to
gather information about a small number of these parameters (in fact, trials
often focus on a single primary outcome to be estimated reliably). We denote
these targeted parameters φ and it is only these parameters that we must ex-
plore intelligently to estimate the expected posterior variance. Specifically, it
is suggested that Q evenly spaced values for φ should be chosen from the PSA
samples for φ. These Q values are then used to simulate one future sample from
X | φ for each φ value, resulting in Q simulated datasets.
A posterior distribution is then found for each simulated future sample.
This gives Q posterior distributions, which will usually be found using MCMC
simulation through computer programs such as BUGS [26], JAGS [30] or Stan
[11]. For each posterior distribution, we then need to calculate the variance of
the net benefit in order to approximate the EVSI using moment matching. In
general, Q should be greater than 20 to obtain sufficiently accurate estimates
of the variance. However, as Q increases, the EVSI estimate becomes more
accurate, although at the cost of longer computational time. Estimating the
variance in this manner implies that our method can be used irrespective of the
underlying model structure, provided it is computationally feasible to find the
posterior distribution by MCMC simulation Q times.
2.4 Calculating the EVSI for a specific set of treatment
options
To calculate the EVSI using this estimated distribution of the preposterior mean,
it is necessary to determine the joint distribution of the preposterior mean net
benefit across all the different treatment options. Theoretically, this adds lit-
tle complication to the method already described in that a posterior variance-
covariance matrix for all the net benefits must be estimated, instead of a scalar
variance.
However, the EVSI estimate is more stable computationally if the incremen-
tal net benefit (INB) of treatment r versus treatment s, defined as INBθ =
NBθr −NBθs , is used instead. In this case, the optimal treatment, under current
or future information, is found by comparing the INB with 0. For example, if
only two treatment options are considered, then treatment t = 2 is optimal if
the INB is positive while t = 1 is optimal if it is negative. More importantly,
if the distribution of the preposterior mean of the INB is estimated using the
moment matching method, the EVSI is computed as
EX
[
max
{
0,Eθ|X
[
INBθ
]}]
−max
{
0,Eθ
[
INBθ
]}
,
where µX = Eθ|X
[
INBθ
]
and the mean and variance of the INB are scalars
rather than matrices.
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When more than two treatment options are being compared, working with
the INB reduces the size of the posterior variance-covariance matrix that must be
estimated, leading to greater numerical stability. For example, if three treatment
options are considered, using the INB implies that only three unique elements
must be estimated in the posterior variance-covariance matrix rather than 6.
2.5 Nuisance Parameters
Finally, an extension to the method presented so far is needed to reflect the fact
that the new research only informs a small subset of the model parameters φ,
as discussed in §2.3. In general, it is unlikely that the distribution for INBθ,
conditional on all the underlying model parameters θ, will be the same as the
distribution of the preposterior mean for data informing φ. Therefore, it is
necessary to determine the distribution of the INB conditional solely on φ,
indicated as INBφ. It is then these samples of INBφ that are rescaled linearly
to moment match with the distribution of the preposterior mean.
To demonstrate the difference between INBθ and INBφ, we consider a simple
two parameter model where: φ ∼ Beta(1, 4), ψ ∼ Normal(−0.5, 1), NBθ0 =
10 000ψ−4 000; NBθ1 = 10 000φ−6 500; and INBθ = 10 000 (φ − ψ) − 2 500.
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Figure 1: The distribution of the incremental net benefit conditional on both
the model parameters θ (LHS) and conditional on the parameter of interest φ
(RHS).
Figure 1 shows that the prior for INBθ is approximately normal — particu-
larly in the tails — while, as the INB is linear in φ, the distribution of INBφ is
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a shifted and scaled Beta distribution, which is non-normal. Therefore, if INBθ
was used to approximate the distribution of the preposterior mean for new re-
search that only informs the parameter φ then the shape of that approximate
distribution would be incorrect, leading to inaccurate estimates for the EVSI.
To identify a more appropriate shape for the distribution of the preposterior
mean in the presence of nuisance parameters, i.e. the parameters ψ such that
θ = (φ,ψ), the uncertainty due to ψ should be marginalised out by calculating:
INBφ = Eψ|φ
[
INBθ
]
. (3)
While calculating this expectation can be computationally intensive, it should
be estimated before proceeding to calculate the EVSI [38]. This is because
calculating the EVSI requires a study design for the future research which is
time consuming to determine for a realistic trial. Therefore, before designing the
trial, the value of resolving all the uncertainty in φ should be calculated. This
is known as the Expected Value of Partial Perfect Information (EVPPI) and is
based on the expectation in (3). Consequently, samples of INBφ should already
have been calculated. However, if these values are not available, Strong et al.
[36] or Heath et al. [22] offer computationally efficient procedures for estimating
this expectation using non-parametric regression, with code available in the R
package bcea [4] or as a stand-alone function [35].
Finally, to rescale the sample of the INBφ, rather than INBθ, the constant
a from §2 becomes:
a =
σ√
VarφINB
φ
,
where σ is the variance of the preposterior mean. Note that σ must still be
calculated as a function of the variance of INBθ — not the variance of INBφ —
and the posterior variance, as outlined in §2.3.
3 Case Study: Ades et al. Decision Tree Model
To demonstrate the effectiveness of our methodology, we use a decision tree
model developed in Ades et al. [1]. This model has two treatment options, a
standard of care and a new treatment, aimed at avoiding a critical event. This
critical event leads to a reduction in QALYs for the remainder of the patient’s
life. The new treatment reduces the probability of the critical event but the
patient may also experience side effects which give a short term reduction in
QALYs along with a direct cost of additional treatment. The model has 11
parameters, of which 4 are subject to uncertainty which is then modelled using
4 mutually independent distributions; a complete model description is given in
Ades et al. [1] or Strong et al. [37].
For this case study, we consider four different data collection exercises, the
first three have been tackled by Ades et al. and the fourth investigates the
moment matching method when φ is not unidimensional;
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1. To reduce uncertainty in the probability of side effects for the new treat-
ment φ1, 60 patients are given the new treatment and the number who
suffer from side effects is recorded.
2. To reduce uncertainty in the quality of life after the critical event φ2, the
quality of life for 100 patients who experienced the event is recorded.
3. To reduce uncertainty in the odds ratio of the effectiveness of the two
treatments φ3, a randomised control trial with 200 patients on each arm
is undertaken.
4. To reduce uncertainty in the probability of the critical events in both
treatment arms φC3 , φ
T
3 , the same randomised control trial is undertaken
but the analysis informs these two probabilities directly.
For a full description of the distributional assumptions for these studies, partic-
ularly the difference between study 3 and study 4, see Strong et al. [37].
3.1 Computations
To calculate the EVSI using the moment matching methodology, 1 000 000 sim-
ulations were taken for the 4 stochastic model parameters. These were then
combined with the other seven parameters to calculate 1 000 000 simulations for
the INB under current information. These simulations for INBθ were used to
find INBφ using GAM regression [21] obtained with the gam function from the
mgcv package [42] in R. The simulations were also used to find the mean and
variance of INBθ.
To estimate the preposterior variance, the expected posterior variance was
estimated using MCMC procedures with Q, the number of φ values, equal to 30.
This was achieved using JAGS through R [29] with 10 000 simulations from each
posterior distribution and 1 000 simulations used as burn-in. This means that
in total 1 330 000 simulations were used to estimate the EVSI in this example,
although note that the PSA simulations were reused for each EVSI calculation.
Fewer simulations could be used but as this example has a small computational
cost it was possible to use this number of simulations to improve the accuracy
of the methods. The computational time required to estimate the posterior
variance with this number of simulations was between 3.8-6.1 seconds.
To assess the accuracy of our method, the expected posterior variance was
estimated using the above procedure 1 000 times for each trial. Each of these
estimates for the expected posterior variance was then used to approximate
the EVSI using moment matching to give a distribution for the EVSI estimate
obtained using moment matching. In a standard analysis, therefore, our method
would produce a point estimate for the EVSI rather than the distributions given
in §3.2.
To determine the accuracy of our method, we compared with the compu-
tationally intensive two-step nested Monte Carlo procedure [9] and the Strong
et al. method [37] based on sufficient statistics and non-parametric regression
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which is an accurate and efficient estimation method for models where the data
can be summarised using a low dimensional sufficient statistic. For the exper-
iments targeting φ1, φ2 and φ3, the comparator values are taken directly from
the Strong et al. paper where the estimates are based on 1010 and 106 simula-
tions respectively. For the two parameter EVSI estimate, the results for these
two methods were obtained using the same number of simulations using code
given in the supplementary material. The computational times to obtain these
estimates were 8.4 seconds for the Strong et al. method and 207 595 seconds
(approximately 2.4 days) for the nested Monte Carlo method.
3.2 Results
Figure 2 plots the sampling distribution of the EVSI estimate, over the differ-
ent estimates of the expected posterior variance, obtained using our moment
matching method for the four alternative study designs. The solid line gives
the value of the estimate obtained by nested Monte Carlo (which can be consid-
ered as the “truth”), the dashed line is the estimate obtained using the Strong
et al. method and the dotted line is the average moment matching estimate.
Evidently, the moment matching method is in line with these two alternative
estimation methods for the studies considered, although the two-parameter esti-
mation has a slight upward bias. Nonetheless, the true EVSI value is well within
the 90% interval, represented by the solid black line on the axis in Figure 2.
Figure 2 also demonstrates that the EVSI estimate calculated using moment
matching is less accurate for experiments with smaller EVSI — as the EVSI gets
smaller, the 90% intervals get wider. This is because the estimate is based on the
difference between the prior variance and the expected posterior variance. When
the EVSI is small then this difference is also small and therefore the posterior
and prior variance needs to be estimated with greater precision because the
difference can be greatly affected by the Monte Carlo error in the variance
estimation. It is important to note that the accuracy demonstrated in Figure 2
depends on accurately estimating the prior variance. Therefore, our moment
matching method should not be used if the initial PSA simulation size is very
small.
4 Discussion
We have presented an estimation method that reduces the significant computa-
tional burden required to estimate the EVSI accurately. This method is based
on using information already available to the researcher, typically in the form
of PSA simulations, a relationship that is also exploited by Menzies [27] de-
spite large differences between the two methods. Our method involves moment
matching by performing a linear transformation of the PSA simulations for the
incremental net benefit. To perform this matching, nested sampling is used
to calculate the expected posterior variance across different samples. For the
example in this paper, the required number of nested simulations was reduced
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Figure 2: The “sampling distribution” of the EVSI conditional on the distribu-
tion over the different estimates for the variance of the preposterior mean for φ1,
φ2 and φ3 for the Ades et al. example [1]. The solid red line represents the EVSI
calculated using Monte Carlo methods and 1010 simulations. The dashed blue
line represents the EVSI estimate obtained using the Strong et al. method with
106 simulations. The dotted brown line represents the average EVSI estimate
obtained using moment matching and the solid black horizontal line represents
the 90% interval for this estimation method. The comparator methods (MC
and Strong et al.) are taken from Strong et al. [37] for the first three graphics.
from 106 to 30, offering a significant computational saving especially in more
complex models where running the model has a computational cost.
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4.1 When should this method be used?
Several methods have been proposed for estimating the EVSI. A large number
of these are restricted to models that fulfil certain conditions, either on the
economic model being used or the structure of the data, or potentially both [41,
8, 1, 24]. The moment matching method is likely to have a higher computational
cost than these methods but can be used in any setting. Current general purpose
methods, i.e. those that can be used irrespective of the underlying model, include
the one presented by Strong et al., used as a comparator in this paper, the one
developed by Menzies [27] and a method based on Laplace approximations to
bypass the use of MCMC to perform the Bayesian updating [25, 7].
Firstly, provided a low-dimensional sufficient statistic is available to capture
all the information contained in the sample, the Strong et al. [37] method typi-
cally outperforms the other methods in terms of computational time. However,
it may be challenging to determine an appropriate sufficient statistic, particu-
larly for complex designs. The Menzies [27] method also avoids the need for
additional model runs but does involve a large number of matrix operations,
which has a significant computational cost when the number of PSA simula-
tions is large. Therefore, the moment matching method can be significantly
faster than this alternative when the model itself has a relatively small compu-
tational cost. Conversely, if the underlying health economic model is computa-
tionally intensive to run it would not feasible to rerun the model a large number
of times and the Menzies method could be used.
Finally, using Laplace approximations requires T (2p+ 1) model evaluations,
where p is the number of model parameters and T the number of treatment
options [7]. It also involves numerical optimisation, which has an associated
computational cost. Nonetheless, this method could be more efficient than our
moment matching method in health economic models with a small number of
underlying parameters but a long run time.
In conclusion, the moment matching method presented in this paper is a
computationally efficient method for estimating the EVSI and is most helpful
in cases where a sufficient statistic for the data is difficult to specify but the
computational time taken to run the model itself is relatively small, although it
can be competitive in terms of computational time for simple models. Therefore,
we believe this method is an important addition to EVSI literature as it is based
solely on Bayesian updating which typically must be designed in order to analyse
the data once the experiment has been performed. If the research goes ahead,
the calculation of the EVSI will aid in modelling trial results as researchers can
use the procedure that has already been defined.
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A The distribution of the preposterior mean
To explore the similarity between the prior and the distribution of the prepos-
terior mean two examples are presented.
A.1 Exponential Gamma Model
For the first example, a Gamma prior is assumed for the parameter of interest
θ ∼ Gamma(α, β). The data collection exercise is then assumed to be N
independent observations from an exponential distribution conditional on θ;
Xj ∼ Exp(θ) with j = 1, . . . , N . The distribution of the preposterior mean is
then considered for different values of N , where the two net benefit functions
are:
NBθ0 = c0 and NB
θ
1 = kθ − c1.
Figure 3 presents the distribution of the preposterior mean for NBθ1 for α = 5,
β = 1, k = 200, c0 = 900 and c1 = 100.
Firstly, observe that the distribution of the preposterior mean approaches
the distribution of the prior for NB1 the sample size of the future data increases.
Additionally, notice that the distribution become more variable as the sample
size increases. These two comments are seemingly at odds with our intuition
about the distribution of a mean — that the distribution becomes more normal
and less variable as the sample size of the data increases.
However, these counterintuitive properties hold because the “strength” of
the data increases as the sample size increases. This implies that the posterior
mean can deviate further from the prior mean as the sample size increases. The
distribution of the preposterior mean is the distribution over all possible future
means, which can be further from the prior mean as the size of the future data
collection increases. More importantly, the distribution of the preposterior mean
tends to the prior because an infinite data collection exercise would determine
the exact value of the parameter θ. However, at this current state of knowledge,
i.e. before the data collection has taken place, we believe that θ follows the prior
distribution. Therefore, the distribution of the mean with this infinite data
collection exercise is equal to the prior. This can be seen analytically using
normal-normal conjugacy.
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Figure 3: The distribution of the exact preposterior mean for different samples
sizes using Exponential-Gamma conjugacy, with the prior for the net benefit
marked in black.
A.2 Normal Normal Model
For this example, the prior for θ is taken as
θ ∼ N(θ0, σ2θ)
while the data collection exercise is N independent samples from
Xi ∼ N(θ, σ2X).
It is then assumed that the variances σ2θ and σ
2
X are known. This implies that
the sample mean of X has a normal distribution, conditional θ and that the
prior-predictive distribution for X¯ is
X¯ ∼ N
(
θ0, σ
2
θ +
σ2X
N
)
.
Finally, the net benefit functions for this example are given by
NBθ0 = 0 and NB
θ
1 = kθ − c.
The preposterior mean for the INB is then
Eθ|X(INB
θ) = k
(
σ2X
σ2X +Nσ
2
θ
θ0 +
σ2θ
σ2X
N + σ
2
θ
X¯
)
− c,
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which is a linear function of a normal distribution. Therefore, the distribution
of the preposterior mean is normal with mean and variance equal to the mean
and variance of the preposterior mean;
Eθ|X(INB
θ) ∼ N
(
kθ0 − c, k2 σ
4
θ
σ2X
N + σ
2
θ
)
.
Firstly, note that the moment matching approximation for the distribution
of the preposterior mean is a INBθ + b. This is also a linear combination of a
normal distribution implying that this approximation is exactly equal to the true
distribution of the preposterior mean for the normal-normal conjugate setting.
Secondly, note that as N →∞, it is clear that the variance of the preposte-
rior mean INBθ tends to k2σ2θ , meaning that the distribution of the preposterior
mean tends to the prior for the incremental net benefit. Another way to think
of this is that, as N → ∞, the sample mean X¯ is tends to the mean of Xi.
However, in a Bayesian setting, the underlying mean θ is subject to uncertainty
modeled using the prior.
Additionally, observe that, as the sample size increases, the denominator of
the variance decreases. Clearly, therefore, the distribution of the preposterior
mean gets more variable as the sample size increases. Again, this confirms
as more information is contained in the data, i.e. the sample size increases,
the posterior mean can be “pulled” further from the prior mean and so the
distribution of the preposterior mean becomes more variable.
Finally, it is trivial to see how the distribution of the preposterior mean is
dependent on the prior. Firstly, is it centred on the prior mean. In addition to
this, the variance of the distribution of the preposterior mean is strongly influ-
enced by the prior variance for realistic sample sizes. Finally, the distributional
assumptions for the prior clearly impact the distribution of the preposterior
mean. Therefore, the moment matching method simply utilises this informa-
tion as typically we will already have access to samples from the prior.
These analytical results give confirmation that the moment matching method
will be suitable in normal-normal settings. This next section briefly discusses
why this method is suitable in other settings.
A.3 Using moment matching to estimate the distribution
of the preposterior mean
Firstly, consider whether the approximation is suitable in two extreme cases.
At one extreme, assume that X is independent of the underlying model param-
eters: p(X | θ) = p(X). Evidently, this setting would never occur as decision
makers only consider data collection that would aid the decision making pro-
cess. Nevertheless, if the sample is independent of the model parameters then
the distribution of the preposterior mean is a point mass at the prior mean
Eθ|X
[
NBθt
]
= Eθ
[
NBθt
]
,
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by the condition of independence.
Using the definition for the constants a and b from the main paper, note
that
a =
√√√√√Var
[
Eθ|X
[
NBθt
]]
Varθ
[
NBθt
] = 0
and
b = Eθ
[
NBθt
]
(1− a) = Eθ
[
NBθt
]
.
Therefore, the moment matching approximation is also equal to the prior mean.
This means that, if X is independent, the moment matching approximation is
exact. Clearly, this is a relatively unimportant result in practice but it does
indicate that the approximation is roughly accurate when the variance of the
preposterior mean is small.
At the other end of the scale, it can be shown that the moment matching
approximation is exact when the sample is deterministically linked to the model
parameters, i.e. X = h(θ) for some h(·). In this setting the conditional mean
for the net benefit is equal to the net benefit since, if the value for X is known,
then the exact NBθt value is also known. In a similar manner to above it can be
shown that a = 1 and b = 0 so the approximation for the distribution of the pre-
posterior mean is equal to NBθt which, again, is exactly as required. Therefore,
as the variance of the preposterior mean increases, the approximation becomes
exact for all distributions. This has a practical implication since, provided the
posterior is consistent, this approximation is accurate for large sample sizes.
To extend these ideas, this approximation is accurate for moderate N when
the posterior mean net benefit is a weighted average between the prior mean
and a data summary
Eθ|X
[
NBθt
]
= c Eθ
[
NBθt
]
+ d g(X),
where c and d are constants and g(·) is an arbitrarily complex function of the
data which must have a similar density to NBθt . As seen previously, this is true
in approximately normal settings and additionally, the first condition is true for
all conjugate settings in the exponential family [16]. Determining whether the
second condition is true is more challenging but in general it holds sufficiently
well provided N > 20.
The following examples demonstrate that for very small sample sizes the
moment matching approximation can give biased estimates in non-normal set-
tings. However, this bias is minimal for realistic sample sizes and decreases as
the sample size N increases past about 20.
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B Examples
B.1 Discrete Sampling
To consider the moment matching approximating for discrete samples, the ex-
ample from the paper is considered. Recall that the parameter θ is modelled
using a uniform prior θ ∼ Uniform(1, 1) and the data have a binomial distri-
bution X | θ ∼ Bin(N, θ). The two net benefit functions are then NBθ0 = 0 and
NBθ1 = kθ − c.
In this setting, the approximation of the distribution of the preposterior
mean could be poor, as X is discrete. This implies that the distribution of
the preposterior mean is discrete, while the prior for NBθ1 is continuous. For
example, when the binomial sample size N = 1, there are 2 equally likely
possible samples, X = 0 and X = 1, implying that there are two equally likely
possible preposterior means; µ01 =
k
3−c or µ11 = 2k3 −c. Clearly, this distribution
can never be well approximated by a shifted and rescaled beta distribution.
Nonetheless, to investigate when a continuous approximation is suitably ac-
curate, the EVSI is estimated for different binomial sample sizes N . As conju-
gate models are used, it is possible to calculate both the EVSI and the variance
of the preposterior mean analytically. The true variance of the preposterior
mean is then used to rescale the simulated observations from INBθ. While the
variance of the preposterior mean is known, the moment matching estimator
for the EVSI is still random as simulated values are taken from the prior for θ.
Therefore, 10 000 different simulations of size 10 000 were taken from the prior
for θ and used to calculate the EVSI. This gives the sampling distribution of
the EVSI estimator which should be centred on the true value for the EVSI.
Figure 4 shows the sampling distribution of the EVSI estimator for different
N where the red line gives the true EVSI. Clearly the EVSI estimator for N = 1
has a significant downward bias as the sampling distribution does not include the
true EVSI value of 1667 (top LHS). Therefore, the weighted prior distribution
is not a suitable approximation for the distribution of the preposterior mean for
N = 1. However, as N increases, the bias decreases, becoming negligible for
N = 10. Therefore, even if the distribution of the preposterior mean is discrete,
the moment matching approximation is suitably accurate when N is sufficiently
large.
B.2 Non-linear mean function with Exponential-Gamma
Example
To investigate the moment matching further consider, the Gamma-Exponential
example: θ ∼ Gamma(α, β), Xj ∼ Exp(θ), j = 1, . . . , N and net benefit
functions are:
NBθ0 = c0 and NB
θ
1 = kθ − c1,
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Figure 4: The distribution of the EVSI estimator over 10 000 different simula-
tions from the prior of θ for 4 different sample sizes for X for the Beta-Binomial
conjugate model. The red line represents the analytical value of the EVSI.
with α = 5, β = 1, k = 200 and c0 = 900 and c1 = 100 as in Figure 3. This
implies that the preposterior mean is equal to
µX1 = Eθ|X
[
NBθ1
]
= k
α+N
β +
∑N
i=1Xi
− c1,
which, in turn, means that both the variance of the preposterior mean and the
EVSI can be found analytically. Therefore, poor estimation of the EVSI using
moment matching is because the distribution of the data summary is not similar
enough to the prior.
Figure 5 shows the sampling distribution of the EVSI values, over different
prior samples, for different values of N . Clearly, the moment matching approx-
imation gives a biased EVSI estimate for small samples. However, this bias is
at most 4% of the total EVSI value, meaning that it is likely to be sufficiently
accurate for decision making. However, note that the EVSI estimate is slightly
biased for small sample sizes so this method performs better with more realistic
sample sizes. This is because the distribution of the preposterior mean tends to
the prior as the sample size increases, see Figure 3.
24
Histogram of EVSI Approximation; N=5
EVSI
D
en
si
ty
110 115 120 125
0.
00
0.
10
0.
20
Histogram of EVSI Approximation; N=10
EVSI
D
en
si
ty
130 135 140 145
0.
00
0.
10
Histogram of EVSI Approximation; N=20
EVSI
D
en
si
ty
145 150 155 160
0.
00
0.
10
Histogram of EVSI Approximation; N=40
EVSI
D
en
si
ty
155 160 165 170
0.
00
0.
10
Figure 5: The distribution of the EVSI estimator over 10 000 different simula-
tions from the prior of θ for 4 different samples sizes forX using the Exponential-
Gamma conjugate model. The red line represents the analytic value of the EVSI,
C Estimating the variance of the preposterior
mean
To investigate whether quadrature is suitable when the prior for the INBθ is
highly non-normal, we introduce a new model. In this setting, INBθ = θ2 − 5
where θ is normal a priori with mean 0 and precision 0.2: θ ∼ N (0, 5). The
data collection is then assumed to be 10 independent observations Xj ∼ N(θ, 1)
for j = 1, . . . , 10. We can easily find the posterior for θ efficiently but the form
of the INB induces a highly non-normal prior. In this setting, the EVSI and
the variance of the preposterior mean are estimated using efficient Monte Carlo
methods [1] with 10 000 samples from the prior for the INBθ. The EVSI is
estimated as 2.00 and the variance of the preposterior mean is 35.20.
Recall that the estimation method for the variance of the preposterior mean
requires Q points spaced throughout the PSA values of θ. In this practise, these
are the Q quantiles for θ, i.e. the S qQ+1–th θ values in an ordered sample, with
q = 1, . . . , Q. Figure 6 then shows the average estimate, over 500 posterior
simulations of 1 000, of the preposterior variance for increasing values of Q up
to Q = 100 — this means that 1 000 simulations were taken from Q different
posterior distributions to estimate the variance of the preposterior mean and
then this was repeated 500 times to give a measure of accuracy. The red line
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Figure 6: The estimate of the variance of the preposterior mean for increasing
numbers of quadrature points. The red line gives the variance of the preposterior
mean calculated using all the samples in the prior for θ. The dashed lines are
the standard errors for the estimates of the variance of the preposterior mean.
in Figure 6 is the variance of the preposterior distribution estimated using the
method from Ades et al. [1]. The dashed lines indicate plus or minus one
standard deviation from the mean estimate of the variance of the preposterior
distribution for the different values of Q.
In general, the estimation method for the variance of the preposterior mean
produces biased estimates for small values of Q. However, when Q > 30, the
true variance is within one standard deviation of the average estimate for the
variance of the preposterior mean. Note also that the estimate becomes more
accurate as Q increases but this is at the cost of computational time. Therefore,
it is recommended to keep Q between 30 and 50.
Table 1: The EVSI estimate for different numbers of posterior samples using
the moment matching method.
Number of simulations 1 2 3 5 8 10 ∞
Estimate of EVSI 2.30 2.24 2.20 2.16 2.12 2.10 2.00
Percentage Bias 0.15 0.12 0.10 0.08 0.06 0.05 0.00
Number of simulations 20 30 40 50 75 100 ∞
Estimate of EVSI 2.06 2.05 2.03 2.02 2.01 2.01 2.00
Percentage Bias 0.03 0.02 0.02 0.01 0.01 0.01 0.00
To confirm this, table 1 records the EVSI estimate and its bias due to using
the moment matching method and the variance estimates in Figure 6. Note
that, the EVSI is upwardly biased by this bias drops below 0.02% for Q >
26
30. Therefore, a relatively small number of quadrature points can be used to
estimate the variance of the preposterior mean, even in significantly non-normal
settings.
D Code to calculate the EVSI for φT3 and φ
C
3
set.seed(2000)
library(mgcv)
library(boot)
library(R2jags)
###Prior for INB###
N<-1000000
L<-30
Qe<-inv.logit(rnorm(N,0.6,sqrt(1/6)))
Qse<-1
Ce<-200000
Ct<-15000
Cse<-100000
Pc<-rbeta(N,15,85)
Pse<-rbeta(N,3,9)
OR<-exp(rnorm(N,-1.5,sqrt(1/3)))
Pt<-inv.logit(log(Pc/(1-Pc))+log(OR))
lambda<-75000
NB1<-Pc*(lambda*L*(1+Qe)/2-Ce)+
(1-Pc)*lambda*L
NB2<-Pse*Pt*(lambda*(L*(1+Qe)/2-Qse)-(Ct+Cse+Ce))+
Pse*(1-Pt)*(lambda*(L-Qse)-(Ct+Cse))+
(1-Pse)*Pt*(lambda*L*(1+Qe)/2-(Ct+Ce))+
(1-Pse)*(1-Pt)*(lambda*L-Ct)
INB<-NB2-NB1
###Prior Variance###
pr.var<-var(INB)
###Strong et al. Method
Dc<-rbinom(1e+06,200,Pc)
Dt<-rbinom(1e+06,200,Pt)
fitted.X<-gam(INB~te(Dc,Dt))$fitted
EVSI.Strong<-mean(pmax(fitted.X,0))-max(mean(fitted.X))
###Moment Matching
#JAGS model
model<-function(){
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Pc~dbeta(15,85)
Pse~dbeta(3,9)
OR.log~dnorm(-1.5,3)
OR<-exp(OR.log)
Pt<-exp(log(Pc/(1-Pc))+OR.log)/(exp(log(Pc/(1-Pc))+OR.log)+1)
Qe.log~dnorm(0.6,6)
Qe<-exp(Qe.log)/(exp(Qe.log)+1)
#Future Sample
Dc~dbin(Pc,200)
Dt~dbin(Pt,200)
NB1<-Pc*(lambda*L*(1+Qe)/2-Ce)+
(1-Pc)*lambda*L
NB2<-Pse*Pt*(lambda*(L*(1+Qe)/2-Qse)-(Ct+Cse+Ce))+
Pse*(1-Pt)*(lambda*(L-Qse)-(Ct+Cse))+
(1-Pse)*Pt*(lambda*L*(1+Qe)/2-(Ct+Ce))+
(1-Pse)*(1-Pt)*(lambda*L-Ct)
INB<-NB2-NB1
}
Q<-30
var.post<-array()
#Calculate the posterior variance
for(i in 1:Q){
#Sample the data
Dc<-rbinom(1,200,quantile(Pc,i/(Q+1)))
Dt<-rbinom(1,200,quantile(Pt,i/(Q+1)))
#Running the JAGS model
dataJags <- list(Dt=Dt,Dc=Dc,L=L,Qse=Qse,Ce=Ce,Ct=Ct,Cse=Cse,lambda=lambda)
params<-c("INB","Pt","Pc")
n.iter <- 10000
n.burnin <- 1000
post <- jags(dataJags, inits=NULL, params, model=model, n.iter=n.iter,
n.burnin=n.burnin,DIC=FALSE)
#Calculate posterior variance
var.post[i]<-var(post$BUGSoutput$sims.list$INB)
}
#Calculating EVSI
fitted.full<-gam(INB~te(Pc,Pt))$fitted
sd.prepost<-sqrt(pr.var-mean(var.post))
#Perform moment matching
samp.prepost<-(fitted.full-mean(fitted.full))/sd(fitted.full)*
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sd.prepost+mean(fitted.full)
EVSI.MM<-mean(pmax(0,samp.prepost))-max(0,mean(samp.prepost))
###Full MCMC
###NOTE: This takes around 2.5 days to run.
mean.post<-array()
for(i in 1:1e+06){
#Future data
Dc<-rbinom(1,200,Pc[i])
Dt<-rbinom(1,200,Pt[i])
#Running the Bayesian model
dataJags <- list(Dt=Dt,Dc=Dc,L=L,Qse=Qse,Ce=Ce,Ct=Ct,Cse=Cse,lambda=lambda)
params<-c("INB","Pt","Pc")
n.iter <- 10000
n.burnin <- 1000
vaccine <- jags(dataJags, inits=NULL, params, model=model,n.iter=n.iter,
n.burnin=n.burnin,DIC=FALSE)
#Calculate the posterior mean
mean.post[i]<-mean(vaccine$BUGSoutput$sims.list$INB)
}
EVSI.MCMC<-mean(pmax(0,mean.post))-max(0,mean(mean.post))
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